Early events during neoplastic progression in Barrett's esophagus

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 307-324

  Reid, Brian J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

aneuploidy; Barrett's esophagus; biomarkers; chromosome instability; clonal evolution; clonal expansion; dysplasia; esophageal adenocarcinoma; gastroesophageal reflux disease (GERD); genetic diversity; genome instability; hitchhikers ("passengers"); nonsteroidal anti inflammatory drugs; Peter Nowell; SNP arrays; telomeres

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER GROWTH; CHROMOSOMAL INSTABILITY; COHORT ANALYSIS; DNA DETERMINATION; DRUG USE; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; HETEROZYGOSITY LOSS; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPLOIDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; CHROMOSOMAL INSTABILITY; DISEASE PROGRESSION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 82955246336     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0162     Document Type: Article

References (185)

1. ACS Cancer Statistics 2009. http://www. acs. org.
2. N. R. Barrett, The lower esophagus lined by columnar epithelium, Surg 41(61957), 881-894.
3. N. Vakil, S. V. van Zanten, P. Kahrilas, J. Dent and R. Jones, The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus, Am J Gastroenterol 101(82006), 1900-1920; quiz 1943.
4. P. Sharma, K. McQuaid, J. Dent et al. , A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop, Gastroenterology 127(12004), 310-330.
5. K. K. Wang and R. E. Sampliner, Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus, Am J Gastroenterol 103(32008), 788-797.
6. C. C. Maley, P. C. Galipeau, X. Li et al. , The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma, Cancer Res 64(202004), 7629-7633.
7. L. Gutierrez-Gonzalez and N. A. Wright, Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration, Dig Liver Dis 40(72008), 510-522.
8. R. C. Orlando, Mucosal Defense in Barrett's Esophagus. In:Barrett's Esophagus and Esophageal Adenocarcinoma; eds S. R. ed. Sharma P. Oxford, UK: Blackwell Publishing, Ltd (2006), 60-72.
9. A. van der Burgh, J. Dees, W. C. Hop and M. van Blankenstein, Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus, Gut 39(11996), 5-8.
10. C. E. Macdonald, A. C. Wicks and R. J. Playford, Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study, BMJ 321(72712000), 1252-1255.
11. L. A. Anderson, L. J. Murray, S. J. Murphy et al. , Mortality in Barrett's oesophagus: results from a population based study, Gut 52(82003), 1081-1084.
12. M. Solaymani-Dodaran, R. F. Logan, J. West and T. Card, Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study, Am J Gastroenterol 100(122005), 2616-2621.
13. P. Moayyedi, N. Burch, N. Akhtar-Danesh et al. , Mortality rates in patients with Barrett's oesophagus, Aliment Pharmacol Ther 27(42008), 316-320.
14. H. Pohl and H. G. Welch, The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence, J Natl Cancer Inst 97(22005), 142-146.
15. R. S. Holmes and T. L. Vaughan, Epidemiology and pathogenesis of esophageal cancer, Sem Rad Oncology, in press.
16. L. M. Brown and S. Devesa, Epidemiologic trends in esophageal and gastric cancer in the United States, Surg Oncol Clin N Am 11, 235-256.
17. T. Thomas, K. R. Abrams, J. S. De Caestecker and R. J. Robinson, Meta analysis: Cancer risk in Barrett's oesophagus, Aliment Pharmacol Ther 26(11-122007), 1465-1477.
18. F. Yousef, C. Cardwell, M. M. Cantwell et al. , The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis, Am J Epidemiol 168(32008), 237-249.
19. L. S. Engel, W. H. Chow, T. L. Vaughan et al. , Population attributable risks of esophageal and gastric cancers, J Natl Cancer 95 (2003), 1404-1413.
20. J. Lagergren, R. Bergstrom, A. Lindgren and O. Nyren, Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma, N Engl J Med 340(111999), 825-831.
21. D. C. Farrow, T. L. Vaughan, C. Sweeney et al. , Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer, Cancer Causes Control 11(32000), 231-238.
22. J. Ronkainen, P. Aro, T. Storskrubb et al. , Prevalence of Barrett's Esophagus in the General Population: An Endoscopic Study, Gastroenterol 129 (2005), 1828-1831.
23. R. M. Zagari, L. Fuccio, M. A. Wallander et al. , Gastrooesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study, Gut 57(102008), 1354-1359.
24. P. J. Kahrilas, N. J. Shaheen and M. F. Vaezi, American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease, Gastroenterology 135(42008), 1392-1413, 1413 e1391-1395.
25. M. T. Barrett, K. Y. Yeung, W. L. Ruzzo et al. , Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae, Neoplasia 4(22002), 121-128.
26. M. T. Barrett, D. Pritchard, C. Palanca-Wessels et al. , Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus, Cancer Res 63(142003), 4211-4217.
27. B. Albrecht, M. Hausmann, H. Zitzelsberger et al. , Arraybased comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma, J Pathol 203(32004), 780-788.
28. J. W. van Baal, F. Milano, A. M. Rygiel et al. , A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia, Gastroenterology 129(42005), 1274-1281.
29. E. T. Kimchi, M. C. Posner, J. O. Park et al. , Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation, Cancer Res 65(82005), 3146-3154.
30. J. Ostrowski, M. Mikula, J. Karczmarski et al. , Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics, J MolMed 85(72007), 733-743.
31. D. M. Greenawalt, C. Duong, G. K. Smyth et al. , Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenarcinoma, and squamous cell carcinoma, Int J Cancer 120(92007), 1914-1921.
32. D. J. Nancarrow, H. Y. Handoko, B. M. Smithers et al. , Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays, Cancer Res 68(112008), 4163-4172.
33. T. G. Paulson, C. C. Maley, X. Li et al. , Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma, Clin Can Res (2009), in press.
34. D. Peng, E. A. Sheta, S. M. Powell et al. , Alterations in Barrett's-related adenocarcinomas: a proteomic approach, Int J Cancer 122(62008), 1303-1310.
35. T. Sjoblom, S. Jones, L. D. Wood et al. , The consensus coding sequences of human breast and colorectal cancers, Science 314(57972006), 268-274.
36. D. W. Parsons, S. Jones, X. Zhang et al. , An integrated genomic analysis of human glioblastoma multiforme, Science 321(58972008), 1807-1812.
37. S. Jones, X. Zhang, D. W. Parsons et al. , Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science 321(58972008), 1801-1806.
38. J. Kaiser, Cancer genetics, A detailed genetic portrait of the deadliest human cancers, Science 321(58942008), 1280-1281.
39. B. J. Reid, R. C. Haggitt, C. E. Rubin et al. , Observer variation in the diagnosis of dysplasia in Barrett's esophagus, Hum Pathol 19(21988), 166-178.
40. E. Montgomery, M. P. Bronner, J. R. Goldblum et al. , Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation, Hum Pathol 32(42001), 368-378.
41. M. Alikhan, D. Rex, A. Khan et al. , Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice, Gastrointest Endosc 50(11999), 23-26.
42. B. J. Reid, D. S. Levine, G. Longton, P. L. Blount and P. S. Rabinovitch, Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets, Am J Gastroenterol 95(72000), 1669-1676.
43. A. P. Weston, P. Sharma, M. Topalovski et al. , Long-term follow-up of Barrett's high-grade dysplasia, Am J Gastroenterol 95 (82000), 1888-1893.
44. N. S. Buttar, K. K. Wang, L. S. Lutzke, K. K. Krishnadath and A. M. A, Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus, Gastrointest Endosc 54(62001), 682-688.
45. T. G. Schnell, S. J. Sontag, G. Chejfec et al. , Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia, Gastroenterology 120(72001), 1607-1619.
46. R. L. Prentice, Surrogate endpoints in clinical trials: definition and operational criteria, Stat Med 8(41989), 431-440.
47. T. R. Fleming, R. L. Prentice, M. S. Pepe and D. Glidden, Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research, Stat Med 13(91994), 955-968.
48. G. S. Dulai, P. G. Shekelle, D. M. Jensen et al. , Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort, Am J Gastroenterol 100(42005), 775-783.
49. M. Conio, S. Blanchi, S. Lapertosa et al. , Long-term endoscopic surveillance of patients with Barrett's esophagus. ncidence of dysplasia and adenocarcinoma: a prospective study, Am J Gastroenterol 98(92003), 1931-1939.
50. P. Sharma, G. W. Falk, A. P. Weston et al. , Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus, Clin Gastroenterol Hepatol 4(52006), 566-572.
51. A. P. Weston, P. Sharma, M. Topalovski, R. Cherian and A. Dixon, Low-grade dysplasia in Barrett's esophagus: variable fate during long-term prospective follow-up, Gastroenterology 116(41999), A352.
52. N. S. Buttar, K. K. Wang, T. J. Sebo et al. , Extent of highgrade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma, Gastroenterology 120(72001), 1630-1639.
53. A. Srivastava, J. L. Hornick, X. Li et al. , Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus, Am J Gastroenterol 102(32007), 483-493; quiz 694.
54. B. J. Reid, W. M. Weinstein, K. J. Lewin et al. , Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions, Gastroenterology 94(11988), 81-90.
55. A. J. Cameron and H. A. Carpenter, Barrett's esophagus, highgrade dysplasia, and early adenocarcinoma: a pathological study, Am J Gastroenterol 92(41997), 586-591.
56. J. E. McArdle, K. J. Lewin, G. Randall andW. Weinstein, Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus [see comments], Hum Pathol 23(51992), 479-482.
57. J. D. Birkmeyer, A. E. Siewers, E. V. Finlayson et al. , Hospital volume and surgical mortality in the United States, N Engl J Med 346(152002), 1128-1137.
58. C. B. Begg, L. D. Cramer, W. J. Hoskins and M. F. Brennan, Impact of hospital volume on operative mortality for major cancer surgery, JAMA 280(201998), 1747-1751.
59. M. G. Patti and D. Owen, Prognostic factors in esophageal cancer, Surg Oncol Clin N Am 6(31997), 515-531.
60. J. B. Dimick, S. M. Cattaneo, P. A. Lipsett, P. J. Pronovost and R. F. H, Hospital Volume is Related to Clinical and Economic Outcomes of Esophageal Resection inMaryland, Ann Thorac Surg 72 (2001), 334-341.
61. J. Jankowski and P. Moayyedi, Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus, J Natl Cancer Inst 96(112004), 885-887; author reply 887.
62. B. F. Overholt, C. J. Lightdale, K. K. Wang et al. , Photodynamic therapy with porfimer sodium for ablation of highgrade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial, Gastrointest Endosc 62(42005), 488-498.
63. B. F. Overholt, K. K. Wang, J. S. Burdick et al. , Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia, Gastrointest Endosc 66(32007), 460-468.
64. N. Shaheen, P. Sharma, B. Overholt et al. , A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial, Gastroenterol 134(42008), A-37.
65. R. W. Phillips and R. K. Wong, Barrett's esophagus. Natural history, incidence, etiology, and complications, Gastroenterol Clin North Am 20(41991), 791-816.
66. C. Iascone, T. R. DeMeester, A. G. Little and D. B. Skinner, Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy, Arch Surg 118(51983), 543-549.
67. R. C. Haggitt, B. J. Reid, P. S. Rabinovitch and C. E. Rubin, Barrett's esophagus. Correlation between mucin histochemistry, flow cy ometry, and histologic diagnosis for predicting increased cancer risk, Am J Pathol 131(11988), 53-61.
68. D. S. Levine, C. E. Rubin, B. J. Reid andR. C. Haggitt, Specialized metaplastic columnar epithelium in Barrett's esophagus. A comparative transmission electron microscopic study, Lab Invest 60 (31989), 418-432.
69. D. S. Levine, B. J. Reid, R. C. Haggitt, C. E. Rubin and P. S. Rabinovitch, Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium, Gastroenterology 96(2 Pt 11989), 355-367.
70. J. Dixon, V. Strugala, S. M. Griffin et al. , Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but present in columnar-lined Barrett's esophagus, Am J Gastroenterol 96(92001), 2575-2583.
71. N. A. Tobey, C. M. Argote, X. C. Vanegas, W. Barlow and R. C. Orlando, Electrical parameters and ion species for active transport in human esophageal stratified squamous epithelium and Barrett's specialized columnar epithelium, Am J Physiol Gastrointest Liver Physiol 293 (12007), G264- 270.
72. B. Jovov, C. M. Van Itallie, N. J. Shaheen et al. , Claudin- 18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance, Am J Physiol Gastrointest Liver Physiol 293(62007), G1106-1113.
73. P. Lao-Sirieix, A. Corovic, J. Jankowski et al. , Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus, Dis Esophagus 21(62008), 529-538.
74. E. R. Fearon, K. R. Cho, J. M. Nigro et al. , Identification of a chromosome 18q gene that is altered in colorectal cancers, Science 247(49381990), 49-56.
75. G. Smith, F. A. Carey, J. Beattie et al. , Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer, Proc Natl Acad Sci U S A 99(142002), 9433-9438.
76. M. J. McKinley, D. R. Budman, D. Grueneberg et al. , DNA content in Barrett's esophagus and esophageal malignancy, Am J Gastroenterol 82(101987), 1012-1015.
77. B. J. Reid, R. C. Haggitt, C. E. Rubin and P. S. Rabinovitch, Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma, Gastroenterology 93(11987), 1-11.
78. M. B. Fennerty, R. E. Sampliner, D. Way et al. , Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus, Gastroenterology 97(41989), 815-820.
79. M. Robaszkiewicz, E. Hardy and A. Volant, Analyse du contenu cellulaire en ADN par cytometrie en flux dans les endobrachyoesophages, Gastroenterol Clin Biol 15 (1991), 703-710.
80. S. Sciallero, W. Giaretti, L. Bonelli et al. , DNA content analysis of Barrett's esophagus by flow cytometry, Endoscopy 25(91993), 648-651.
81. M. B. Menke-Pluymers, A. H. Mulder, W. C. Hop, M. van Blankenstein and H. W. Tilanus, Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group, Gut 35(101994), 1348-1351.
82. E. A. Montgomery, D. P. Hartmann, N. J. Carr et al. , Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies, Am J Clin Pathol 106(31996), 298-304.
83. A. Gimenez, A. Minguela, P. Parrilla et al. , Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus, Cancer 83(41998), 641-651.
84. G. M. Eisen, E. A. Montgomery, N. Azumi et al. , Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials, Gastrointest Endosc 50(61999), 814-818.
85. H. S. Garewal, R. Sampliner, Y. Liu and J. M. Trent, Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma, Cancer Genet Cytogenet 42(21989), 281-286.
86. W. H. Raskind, T. Norwood, D. S. Levine et al. , Persistent clonal areas and clonal expansion in Barrett's esophagus, Cancer Res 52(101992), 2946-2950.
87. M. T. Barrett, P. C. Galipeau, C. A. Sanchez, M. J. Emond and B. J. Reid, Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification andmicrosatellite polymorphisms, Oncogene 12(91996), 1873-1878.
88. Z. T. Hammoud, Z. Kaleem, J. D. Cooper et al. , Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4, Cancer Res 56(191996), 4499-4502.
89. K. Dolan, J. Garde, J. Gosney et al. , Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites, Br J Cancer 78(71998), 950-957.
90. D. Michael, D. G. Beer, C. W. Wilke, D. E. Miller and T. W. Glover, Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas, Oncogene 15(141997), 1653-1659.
91. D. L. Persons, W. S. Croughan, K. A. Borelli and R. Cherian, Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet, Cytogenet 106(11998), 11-17.
92. T. P. Brien, R. D. Odze, C. E. Sheehan, B. J. McKenna and J. S. Ross, HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma, Hum Pathol 31(12000), 35-39.
93. S. H. Doak, G. J. Jenkins, E. M. Parry et al. , Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus, Gut 52(52003), 623-628.
94. M. Fahmy, M. Skacel, T. L. Gramlich et al. , Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens, Mod Pathol 17(52004), 588-596.
95. E. G. Fritcher, S. M. Brankley, B. R. Kipp et al. , A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus, Hum Pathol 39(82008), 1128-1135.
96. V. J. Wongsurawat, J. C. Finley, P. C. Galipeau et al. , Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications foriomarker validation, Cancer Epidemiol Biomarkers Prev 15(32006), 509-516.
97. A. K. Walch, H. F. Zitzelsberger, J. Bruch et al. , Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasiadyspa- carcinoma sequence, Am J Pathol 156(22000), 555-566.
98. P. H. Riegman, K. J. Vissers, J. C. Alers et al. , Genomic alterations in malignant transformation of Barrett's esophagus, Cancer Res 61(72001), 3164-3170.
99. W. El-Rifai, H. F. Frierson, Jr. , C. A. Moskaluk et al. , Genetic differences between adenocarcinomas arising in Barrett's sophagus and gastric mucosa, Gastroenterology 121(32001), 592-598.
100. J. Croft, E. M. Parry, G. J. Jenkins et al. , Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization, Eur J Gastroenterol Hepatol 14(112002), 1179-1186.
101. R. Mei, P. C. Galipeau, C. Prass et al. , Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays, Genome Res 10(82000), 1126-1137.
102. L. A. Lai, T. G. Paulson, X. Li et al. , Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH, Genes Chromosomes Cancer 46(62007), 532-542.
103. X. Li, P. C. Galipeau, C. A. Sanchez et al. , Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression, Cancer Prev Res (Phila Pa) 1(62008), 413-423.
104. K. Neshat, C. A. Sanchez, P. C. Galipeau et al. , Barrett's esophagus: a model of human neoplastic progression, Cold Spring Harb Symp Quant Biol 59 (1994), 577-583.
105. M. T. Barrett, C. A. Sanchez, L. J. Prevo et al. , Evolution of neoplastic cell lineages in Barrett oesophagus, Nat Genet 22(11999), 106-109.
106. C. C. Maley, P. C. Galipeau, X. Li et al. , Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus, Cancer Res 64(102004), 3414-3427.
107. J. Califano, P. L. Leong,W. M. Koch et al. , Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships, Clin Cancer Res 5(71999), 1862-1867.
108. J. J. Lee,W. K. Hong,W. N. Hittelman et al. , Predicting cancer development in oral leukoplakia: ten years of translational research, Clin Cancer Res 6(52000), 1702-1710.
109. D. Sidransky, P. Frost, A. Von Eschenbach et al. , Clonal origin of bladder cancer, N Engl JMed 326(111992), 737-740.
110. W. A. Franklin, A. F. Gazdar, J. Haney et al. ,Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis, J Clin Invest 100(81997), 2133-2137.
111. K. Neshat, C. A. Sanchez, P. C. Galipeau et al. , p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia, Gastroenterology 106(61994), 1589-1595.
112. S. J. Leedham, S. L. Preston, S. A. McDonald et al. , Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus, Gut 57(82008), 1041-1048.
113. P. C. Galipeau, L. J. Prevo, C. A. Sanchez, G. M. Longton and B. J. Reid, Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue, J Natl Cancer Inst 91(241999), 2087-2095.
114. L. J. Prevo, C. A. Sanchez, P. C. Galipeau and B. J. Reid, p53- mutant clones and field effects inBarrett's esophagus, Cancer Res 59(191999), 4784-4787.
115. D. J. Wong, T. G. Paulson, L. J. Prevo et al. , p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium, Cancer Res 61 (2001), 8284-8289.
116. P. C. Galipeau, D. S. Cowan, C. A. Sanchez et al. , 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus, Proc Natl Acad Sci U S A 93 (141996), 7081-7084.
117. P. C. Galipeau, X. Li, P. L. Blount et al. , NSAIDs modulate CDKN2A, TP53, andDNAcontent risk for future esophageal adenocarcinoma, PLoS Med 4 (2007), e67.
118. P. S. Rabinovitch, B. J. Reid, R. C. Haggitt, T. H. Norwood and C. E. Rubin, Progression to cancer in Barrett's esophagus is associated with genomic instability, Lab Invest 60(11989), 65-71.
119. C. C. Maley, P. C. Galipeau, J. C. Finley et al. , Genetic clonal diversity predicts progression to esophageal adenocarcinoma, Nat Genet 38(42006), 468-473.
120. L. Teodori, W. Gohde, M. Persiani et al. , DNA/protein flow cytometry as a predictive marker of malignancy in dysplasiafree Barrett's esophagus: thirteen-year follow-up study on a cohort of patients, Cytometry 34(61998), 257-263.
121. P. S. Rabinovitch, G. Longton, P. L. Blount, D. S. Levine and B. J. Reid, Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables, Am J Gastroenterol 96(112001), 3071-3083.
122. B. J. Reid, L. J. Prevo, P. C. Galipeau et al. , Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression, Am J Gastroenterol 96(102001), 2839-2848.
123. P. L. Blount, P. C. Galipeau, C. A. Sanchez et al. , 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy, Cancer Res 54(91994), 2292-2295.
124. K. Dolan, A. I. Morris, J. R. Gosney, J. K. Field and R. Sutton, Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus, J Gastroenterol Hepatol 18(62003), 683-689.
125. H. D. Kissel, P. C. Galipeau, X. Li and B. J. Reid, Translation of an STR-based biomarker into a clinically compatible SNPbased platform for loss of heterozygosity, Cancer Biomark 5(32009), 143-158.
126. N. A. Lisitsyn, N. M. Lisitsina, G. Dalbagni et al. , Comparative genomic analysis of tumors: detection of DNA losses nd amplification, Proc Natl Acad Sci U S A 92(11995), 151-155.
127. C. M. Gleeson, J. M. Sloan, J. A. McGuigan et al. , Ubiquitous somatic alterations atmicrosatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma, Cancer Res 56(21996), 259-263.
128. H. Shiraishi, T. Mikami, T. Yoshida et al. , Early genetic instability of both epithelial and stromal cells in esophageal squamous cell carcinomas, contrasted with Barrett's adenocarcinomas, J Gastroenterol 41(122006), 1186-1196.
129. D. L. Chao, C. C. Maley, X. Wu et al. ,Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: A prospective analysis, CEBP (2006), in press.
130. R. A. Risques, T. L. Vaughan, X. Li et al. , Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol, Biomarkers Prev 16(122007), 2649-2655.
131. D. C. Farrow, T. L. Vaughan, P. D. Hansten et al. , Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol Biomarkers Prev 7(21998), 97-102.
132. M. J. Thun, M. M. Namboodiri, E. E. Calle,W. D. Flanders and C. W. Heath, Jr. , Aspirin use and risk of fatal cancer, Cancer Res 53(61993), 1322-1327.
133. E. M. Funkhouser and G. B. Sharp, Aspirin and reduced risk of esophageal carcinoma, Cancer 76(71995), 1116-1119.
134. D. A. Corley, K. Kerlikowske, R. Verma and P. Buffler, Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis, Gastroenterology 124(12003), 47-56.
135. T. L. Vaughan, L. M. Dong, P. L. Blount et al. , Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study, Lancet Oncol 6(122005), 945-952.
136. N. S. Buttar, K. K. Wang, O. Leontovich et al. , Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus, Gastroenterology 122(42002), 1101-1112.
137. A. P. Feinberg, R. Ohlsson and S. Henikoff, The epigenetic progenitor origin of human cancer, Nat Rev Genet 7(12006), 21-33.
138. B. Klump, C. J. Hsieh, K. Holzmann, K. Gregor and R. Porschen, Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus, Gastroenterlogy 115(61998), 1381-1386.
139. C. A. Eads, R. V. Lord, S. K. Kurumboor et al. , Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma, Cancer Res 60(182000), 5021-5026.
140. C. A. Eads, R. V. Lord, K. Wickramasinghe et al. , Epigenetic patterns in the progression of esophageal adenocarcinoma, Cancer Res 61(82001), 3410-3418.
141. M. Esteller, P. G. Corn, S. B. Baylin and J. G. Herman, A gene hypermethylation profile of human cancer, Cancer Res 61(82001), 3225-3229.
142. M. V. Brock, M. Gou, Y. Akiyama et al. , Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma, Clin Cancer Res 9(82003), 2912-2919.
143. H. Zou, N. K. Osborn, J. J. Harrington et al. , Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma, Cancer Epidemiol Biomarkers Prev 14(42005), 830-834.
144. L. J. Hardie, S. J. Darnton, Y. L. Wallis et al. , p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations, Cancer Lett 217(22005), 221-230.
145. O. J. Lee, R. Schneider-Stock, P. A. McChesney et al. , Hypermethylation and loss of expression of glutathione peroxidase- 3 in Barrett's tumorigenesis, Neoplasia 7(92005), 854-861.
146. H. Zou, J. R. Molina, J. J. Harrington et al. , Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus, Int J Cancer 116(42005), 584-591.
147. B. A. Onwuegbusi, A. Aitchison, S. F. Chin et al. , Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation, Gut 55(62006), 764-774.
148. J. P. Hamilton, F. Sato, Z. Jin et al. , Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression, Clin Cancer Res 12(222006), 6637-6642.
149. G. Clement, R. Braunschweig, N. Pasquier, F. T. Bosman and J. Benhattar, Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation, J Pathol 208(12006), 100-107.
150. G. Clement, R. Braunschweig, N. Pasquier, F. T. Bosman and J. Benhattar, Alterations of theWnt signaling pathway during the neoplastic progression of Barrett's esophagus, Oncogene 25(212006), 3084-3092.
151. Z. Jin, A. Olaru, J. Yang et al. , Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer, Clin Cancer Res 13(212007), 6293-6300.
152. Z. Jin, Y. Mori, J. Yang et al. , Hypermethylation of the nellike 1 gene is a common and early event and is associatedwith poor prognosis in early-stage esophageal adenocarcinoma, Oncogene 26(432007), 6332-6340.
153. Z. Jin, J. P. Hamilton, J. Yang et al. , Hypermethylation of the AKAP12 promoter is a biomarker of Barrett'sassociated esophageal neoplastic progression, Cancer Epidemiol Biomarkers Prev 17(12008), 111-117.
154. Z. Jin, Y. Cheng, A. Olaru et al. , Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors, Int J Cancer 123(102008), 2331-2336.
155. E. Smith, N. J. De Young, S. J. Pavey et al. , Similarity of aberrant DNAmethylation in Barrett's esophagus and esophageal adenocarcinoma, Mol Cancer 7 (2008), 75.
156. K. Schulmann, A. Sterian, A. Berki et al. , Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk, Oncogene 24(252005), 4138-4148.
157. F. Sato, Z. Jin, K. Schulmann et al. , Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features, PLoS ONE 3(42008), e1890.
158. R. A. Irizarry, C. Ladd-Acosta, B. Wen et al. , The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores, Nat Genet 41(22009), 178-186.
159. N. Bloushtain-Qimron, J. Yao, M. Shipitsin, R. Maruyama and K. Polyak, Epigenetic patterns of embryonic and adult stem cells, Cell Cycle 8(62009), 809-817.
160. V. K. Rakyan, T. A. Down, N. P. Thorne et al. , An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs), Genome Res 18(92008), 1518-1529.
161. J. J. Herbst, M. M. Berenson, D. W. McCloskey and W. C. Wiser, Cell proliferation in esophageal columnar epithelium (Barrett's esophagus), Gastroenterology 75(41978), 683-687.
162. J. Jankowski, R. McMenemin, C. Yu, D. Hopwood and K. G. Wormsley, Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression, Gut 33(51992), 587-591.
163. S. Y. Iftikhar, R. J. Steele, S. Watson et al. , Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus, Gut 33(61992), 733-737.
164. M. R. Gray, P. A. Hall, J. Nash et al. , Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization, Gastroenterology 103(61992), 1769-1776.
165. P. Gillen, M. McDermott, D. Grehan, D. O. Hourihane and T. P. Hennessy, Proliferating cell nuclear antigen in the assessment of Barrett's mucosa, Br J Surg 81(121994), 1766-1768.
166. M. K. Hong, W. B. Laskin, B. E. Herman et al. , Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus, Cancer 75(21995), 423-429.
167. W. Polkowski, van J. J. Lanschot, F. J. Ten Kate et al. , The value of p53 and Ki67 as markers for tumour progression inthe Barrett's dyspasia-carcinoma sequence, Surg Oncol 4(31995), 163-171.
168. P. S. Sirieix, M. O'Donovan, J. Brown et al. , Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus, Clin Cancer Res 9(72003), 2560-2566.
169. P. Lao-Sirieix, R. Brais, L. Lovat, N. Coleman and R. C. Fitzgerald, Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis, Neoplasia 6(62004), 751-760.
170. P. Lao-Sirieix, L. Lovat and R. C. Fitzgerald, Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance, Clin Cancer Res 13(22007), 659-665.
171. D. L. Chao, C. A. Sanchez, P. C. Galipeau et al. , Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study, Clin Cancer Res 14(212008), 6988-6995.
172. K. Bani-Hani, I. G. Martin, L. J. Hardie et al. , Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma, J Natl Cancer Inst 92(162000), 1316-1321.
173. L. Murray, A. Sedo, M. Scott et al. , TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort, Gut 55(102006), 1390-1397.
174. P. C. Nowell, The clonal evolution of tumor cell populations, Science 194(42601976), 23-28.
175. J. A. Jankowski, N. A. Wright, S. J. Meltzer et al. , Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus, Am J Pathol 154(41999), 965-973.
176. T. G. Paulson, P. C. Galipeau, L. Xu et al. , p16 mutation spectrum in the premalignant conditionBarrett's esophagus, PLoS ONE 3(112008), e3809.
177. M. T. Barrett, C. A. Sanchez, P. C. Galipeau et al. , Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus, Oncogene 13(91996), 1867-1873.
178. L. A. Loeb, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res 51 (1991), 3075-3079.
179. M. A. Nowak, N. L. Komarova, A. Sengupta et al. , The role of chromosomal instability in tumor initiation, Proc Natl Acad Sci U S A 99(252002), 16226-16231.
180. O. M. Sieber, K. Heinimann, P. Gorman et al. , Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC, Proc Natl Acad Sci U S A 99(262002), 16910-16915.
181. H. Rajagopalan, M. A. Nowak, B. Vogelstein and C. Lengauer, The significance of unstable chromosomes in colorectal cancer, Nat Rev Cancer 3 (2003), 695-701.
182. L. A. Loeb, K. R. Loeb and J. P. Anderson, Multiple mutations and cancer, Proc Natl Acad Sci U S A 100(32003), 776-781.
183. S. H. Moolgavkar and E. G. Luebeck, Multistage carcinogenesis and the incidence of human cancer, Genes Chromosomes Cancer 38(42003), 302-306.
184. D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell 100(12000), 57-70.
185. J. Breivik, The evolutionary origin of genetic instability in cancer development, SeminCancer Biol 15(12005), 51-60.